MedTrace Logo

Local Factors in the Onset/Progression of Peri-implantitis: A Retrospective Study

NCT07633912 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-06-08

No results posted yet for this study

Summary

With the increasing burden of peri-implantitis worldwide, interest in the management of this pathology has flourished. However, there is a lack of consensus in the search for a predictable therapy. Different therapeutic modalities have been advocated. Non-surgical therapy as a sole modality is often insufficient to resolve inflammation. Surgical interventions have demonstrated more favorable results. Among these, evidence supported the application of resective, reconstructive or combined approaches to limit progressive bone loss and achieve soft tissue health. However, to date, the most appropriate modality is unknown and the decision-making process derives from the understanding gained in the management of periodontitis.

A very relevant aspect of peri-implantitis is that the prevalence tends to be higher at the patient level than at the implant level. This indicates that it is a pathology in which there are localized factors that may contribute to the onset and/or perpetuation of the pathology. Some of the factors that have been demonstrated in the literature point to the characteristics of the peri-implant soft tissues, as well as the position of the dental implants. However, the role of each local factor in the predisposition or protection of peri-implant disease or health is still largely unknown. The objective of this study is therefore to evaluate, in partially edentulous patients with multiple implants, the localized factors associated with peri-implantitis.

Conditions

  • Peri-Implantitis

Interventions

DEVICE

Dental implant

Impact of implant-related local factors on the onset/progression of peri-implantitis

Sponsors & Collaborators

  • Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain

    lead OTHER

Principal Investigators

  • Alberto Monje Correa, DDS, MS, PhD · CICOM MONJE

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-10
Primary Completion
2025-01-10
Completion
2025-01-10

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07633912 on ClinicalTrials.gov